Willem van Weperen (SVP International Intercept Pharmaceuticals).
Willem van Weperen holds an MSc in Medical Biology of Utrecht University and obtained his MBA from the NIMBAS-Bradford University. Prior to Intercept, Willem held an international leadership position at Myokardia and Amicus Therapeutics. Prior to Amicus, Willem was CCO of Prosensa, CEO of to-BBB and held various commercial positions at Genzyme.
Joost Thijssen (CEO Florates).
Joost Thijssen holds a MSc in Biochemistry of Utrecht University. Prior to founding Florates, Joost founded Check-Points and he held various sales and marketing positions with PamGene, Quest and Unilever. Check-Points has developed a complete system for fast routine microbial detection and identification in a number of applications. The system is used by the customers in their own routine lab facilities
Arjen van Mierlo (former CEO Endemol Asia).
Arjen van Mierlo holds a MSc in Business Economics from Tilburg University and has extensive experience in investment banking and greenfield operations in various industries. Prior to his current position, Arjen was Executive Director Corporate Strategy & Development and most recently head of international operations of Endemol. Arjen acts as a business angel and is shareholder in several VenGen portfolio companies.
Roel Schaapveld (CEO, InteRNA Technologies).
Roel Schaapveld served as Chief Operating Officer when InteRNA became operational until he was appointed Chief Executive Officer in May 2009. Prior to InteRNA, Roel was senior manager in the corporate finance biotech team at the Dutch merchant bank Kempen & Co involved in private funding, M&A and IPO’s at Euronext of life sciences companies. Previously, he held several management positions at Kreatech Diagnostics (sold to Leica Biosystems), among which VP Corporate and Business Development. Roel holds M.Sc. and Ph.D. degrees from Radboud University Nijmegen (NL). During his academic career he worked at the Roche Institute for Molecular Biology (Nutley, NJ), at the Dana-Farber Cancer Institute (Boston, MA) and at the Netherlands Cancer Institute in Amsterdam. Roel received his MBA from Nyenrode Business School (NL).
Gerben Moolhuizen (CEO ISA Pharmaceuticals).
Gerben Moolhuizen holds an MSc in Medical Biology from Utrecht University and a MBA from Rotterdam School of Management. Prior to joining ISA, Gerben has been CEO of OctoPlus and he held business development positions at Primagen, Pharming and Eurocetus (now Chiron) where he gained more than 14 years experience in making successful deals and obtaining venture capital financing for life science companies.
Michael Muenker (CEO Photonics Healthcare and Founder STEP2). Michael studied in Munich (TU) and Zurich (ETH) and holds a MSc diploma in physics. He worked for ABB in Europe and India, and as a volunteer for Médecins sans Frontières in Africa. He was responsible for medical products and business development at a Munich laser company and moved to The Netherlands in 2004 to become a partner at ELANA. He founded STEP2 in 2008 and helped create the Letters of Utrecht in 2011. Michael founded Photonics Healhcare late in 2009 together with VenGen and Bert Mik, an anesthesiologists and intensivist at the Erasmus Medical Center in Rotterdam.
Fred Dom (CEO HiFiBio). After his graduation in economics at the Erasmus University in Rotterdam, Fred Dom joined in 1993 Rijnvelden investment company, focusing on early stage technology companies. In 1994 he started, RSP Technology BV. a high tech metal company based on an exclusive license from Delft University. Fred is also chairman of an Advisory Committee to the Ministry of Economic Affairs in the field of innovation and entrepreneurship. In July 2007 Fred became CEO of FlexGen, a biotech company based in Leiden, that developed a desktop DNA synthesis instrument.
Willem Fokkema (Technology Transfer Office, University of Amsterdam).
Willem Fokkema holds a MSc in agricultural sciences from Wageningen University. Willem is a business development executive with over twenty years of experience in the food and life science industry. Prior to his current position at the University of Amsterdam, he cofounded LACTIVE with VenGen and held positions at Heineken, Royal Friesland Foods and NIZO food research.
Edwin Klumper (CMO iClusion). Edwin Klumper holds a MD and PhD in Medicine from the Free University, Amsterdam, and obtained his MBA from the Rotterdam School of Management, Erasmus University. During his 18 years of international experience in the Pharma/Biotech Industry Edwin has hold different positions in scientific, commercial and senior management roles at start-up, mid-sized and big-cap biotech companies. During his Amgen tenure Edwin launched a blockbuster drug, turned around the UK business unit before joining Amgen European headquarters as European Brand Director. In 2006 Edwin followed the Pharma/Biotech Executive Leadership Course at Harvard Business School prior to become active as independent Biotech consultant. In 2007 Edwin together with two partners founded SMS-oncology, a CRO specialized in early clinical oncology drug development servicing Pharma/Biotech companies with portfolios in anticancer drugs.